1
|
Palazzo A, Makulyte G, Goerhig D, Médard JJ, Gros V, Trottein F, Adnot S, Vindrieux D, Flaman JM, Bernard D. Benidipine calcium channel blocker promotes the death of cigarette smoke-induced senescent cells and improves lung emphysema. Aging (Albany NY) 2023; 15:13581-13592. [PMID: 38095616 PMCID: PMC10756105 DOI: 10.18632/aging.205259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 10/03/2023] [Indexed: 12/21/2023]
Abstract
Smoking is the main risk factor for many lung diseases including chronic obstructive pulmonary disease. Cigarette smoke (CS) contains carcinogenic and reactive oxygen species that favor DNA mutations and perturb the homeostasis and environment of cells. CS induces lung cell senescence resulting in a stable proliferation arrest and a senescence-associated secretory phenotype. It was recently reported that senescent cell accumulation promotes several lung diseases. In this study, we performed a chemical screen, using an FDA-approved drug library, to identify compounds selectively promoting the death of CS-induced senescent lung cells. Aside from the well-known senolytic, ABT-263, we identified other potentially new senescence-eliminating compounds, including a new class of molecules, the dihydropyridine family of calcium voltage-gated channel (CaV) blockers. Among these blockers, Benidipine, decreased senescent lung cells and ameliorates lung emphysema in a mouse model. The dihydropyridine family of CaV blockers thus constitutes a new class of senolytics that could improve lung diseases. Hence, our work paves the way for further studies on the senolytic activity of CaV blockers in different senescence contexts and age-related diseases.
Collapse
Affiliation(s)
- Alberta Palazzo
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
- Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Gabriela Makulyte
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
- Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Delphine Goerhig
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
- Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Jean-Jacques Médard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
- Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Vincent Gros
- Université Paris Est Créteil, INSERM U955, IMRB, Créteil F-94010, France
- AP-HP, Hôpital Henri Mondor, Département de Physiologie-Explorations Fonctionnelles and FHU Senec, Créteil F-94010, France
| | - François Trottein
- Université Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille F-59000, France
| | - Serge Adnot
- Université Paris Est Créteil, INSERM U955, IMRB, Créteil F-94010, France
- AP-HP, Hôpital Henri Mondor, Département de Physiologie-Explorations Fonctionnelles and FHU Senec, Créteil F-94010, France
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
- Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Jean-Michel Flaman
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
- Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
- Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| |
Collapse
|
2
|
Massemin A, Goehrig D, Flaman J, Jaber S, Griveau A, Djebali S, Marcos E, Payen L, Marvel J, Parent R, Adnot S, Bertolino P, Rieusset J, Tortereau A, Vindrieux D, Bernard D. Loss of Pla2r1 decreases cellular senescence and age-related alterations caused by aging and Western diets. Aging Cell 2023; 22:e13971. [PMID: 37667516 PMCID: PMC10652324 DOI: 10.1111/acel.13971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Revised: 06/21/2023] [Accepted: 08/04/2023] [Indexed: 09/06/2023] Open
Abstract
Cellular senescence is induced by many stresses including telomere shortening, DNA damage, oxidative, or metabolic stresses. Senescent cells are stably cell cycle arrested and they secrete many factors including cytokines and chemokines. Accumulation of senescent cells promotes many age-related alterations and diseases. In this study, we investigated the role of the pro-senescent phospholipase A2 receptor 1 (PLA2R1) in regulating some age-related alterations in old mice and in mice subjected to a Western diet, whereas aged wild-type mice displayed a decreased ability to regulate their glycemia during glucose and insulin tolerance tests, aged Pla2r1 knockout (KO) mice efficiently regulated their glycemia and displayed fewer signs of aging. Loss of Pla2r1 was also found protective against the deleterious effects of a Western diet. Moreover, these Pla2r1 KO mice were partially protected from diet-induced senescent cell accumulation, steatosis, and fibrosis. Together these results support that Pla2r1 drives several age-related alterations, especially in the liver, arising during aging or through a Western diet.
Collapse
Affiliation(s)
- Amélie Massemin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Equipe Labellisée la Ligue Contre le CancerLyonFrance
| | - Delphine Goehrig
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Equipe Labellisée la Ligue Contre le CancerLyonFrance
| | - Jean‐Michel Flaman
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Equipe Labellisée la Ligue Contre le CancerLyonFrance
| | - Sara Jaber
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Audrey Griveau
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Sophia Djebali
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS UMR5308, École Normale Supérieure de LyonUniversité de Lyon, Université Claude Bernard Lyon 1LyonFrance
| | - Elisabeth Marcos
- INSERM U955, Département de Physiologie ‐ Explorations fonctionnelles, Hôpital Henri MondorAP‐HP, FHU SENECCréteilFrance
| | - Léa Payen
- Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Lyon SudHospices Civils de LyonPierre BéniteFrance
| | - Jacqueline Marvel
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS UMR5308, École Normale Supérieure de LyonUniversité de Lyon, Université Claude Bernard Lyon 1LyonFrance
| | - Romain Parent
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Serge Adnot
- INSERM U955, Département de Physiologie ‐ Explorations fonctionnelles, Hôpital Henri MondorAP‐HP, FHU SENECCréteilFrance
| | - Philippe Bertolino
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Equipe Labellisée la Ligue Contre le CancerLyonFrance
| | - Jennifer Rieusset
- CarMeN Laboratory, UMR INSERM U1060/INRA U1397Lyon 1 UniversityPierre béniteFrance
| | - Antonin Tortereau
- VetAgro Sup, Interactions Cellules Environnement (ICE)Université de LyonMarcy l'EtoileFrance
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Equipe Labellisée la Ligue Contre le CancerLyonFrance
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Equipe Labellisée la Ligue Contre le CancerLyonFrance
| |
Collapse
|
3
|
Jaber S, Warnier M, Leers C, Vernier M, Goehrig D, Médard JJ, Vindrieux D, Ziegler DV, Bernard D. Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy. Mol Biomed 2023; 4:4. [PMID: 36739330 PMCID: PMC9899302 DOI: 10.1186/s43556-023-00116-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Accepted: 01/15/2023] [Indexed: 02/06/2023] Open
Abstract
Pancreatic cancer is one of the deadliest cancers owing to its late diagnosis and of the strong resistance to available treatments. Despite a better understanding of the disease in the last two decades, no significant improvement in patient care has been made. Senescent cells are characterized by a stable proliferation arrest and some resistance to cell death. Increasing evidence suggests that multiple lines of antitumor therapy can induce a senescent-like phenotype in cancer cells, which may participate in treatment resistance. In this study, we describe that gemcitabine, a clinically-used drug against pancreatic cancer, induces a senescent-like phenotype in highly chemoresistant pancreatic cancer cells in vitro and in xenografted tumors in vivo. The use of ABT-263, a well-described senolytic compound targeting Bcl2 anti-apoptotic proteins, killed pancreatic gemcitabine-treated senescent-like cancer cells in vitro. In vivo, the combination of gemcitabine and ABT-263 decreased tumor growth, whereas their individual administration had no effect. Together these data highlight the possibility of improving the efficacy of conventional chemotherapies against pancreatic cancer by eliminating senescent-like cancer cells through senolytic intervention. Further studies testing different senolytics or their combination with available treatments will be necessary to optimize preclinical data in mouse models before transferring these findings to clinical trials.
Collapse
Affiliation(s)
- Sara Jaber
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Marine Warnier
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Christopher Leers
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Mathieu Vernier
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France ,Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Delphine Goehrig
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France ,Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Jean-Jacques Médard
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France ,Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - David Vindrieux
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France ,Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| | - Dorian V. Ziegler
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France ,grid.9851.50000 0001 2165 4204Center for Integrative Genomics, University of Lausanne, CH-1015 Lausanne, Switzerland
| | - David Bernard
- grid.25697.3f0000 0001 2172 4233Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France ,Equipe Labellisée la Ligue Contre le Cancer, Lyon, France
| |
Collapse
|
4
|
Palazzo A, Hernandez-Vargas H, Goehrig D, Médard JJ, Vindrieux D, Flaman JM, Bernard D. Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells. Cancer Lett 2022; 546:215850. [DOI: 10.1016/j.canlet.2022.215850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 07/20/2022] [Accepted: 07/26/2022] [Indexed: 11/24/2022]
|
5
|
Raynard C, Ma X, Huna A, Tessier N, Massemin A, Zhu K, Flaman J, Moulin F, Goehrig D, Medard J, Vindrieux D, Treilleux I, Hernandez‐Vargas H, Ducreux S, Martin N, Bernard D. NF-κB-dependent secretome of senescent cells can trigger neuroendocrine transdifferentiation of breast cancer cells. Aging Cell 2022; 21:e13632. [PMID: 35653631 PMCID: PMC9282844 DOI: 10.1111/acel.13632] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 04/22/2022] [Accepted: 05/08/2022] [Indexed: 12/14/2022] Open
Abstract
Cellular senescence is characterized by a stable proliferation arrest in response to stresses and the acquisition of a senescence-associated secretory phenotype, called SASP, composed of numerous factors including pro-inflammatory molecules, proteases, and growth factors. The SASP affects the environment of senescent cells, especially during aging, by inducing and modulating various phenotypes such as paracrine senescence, immune cell activity, and extracellular matrix deposition and organization, which critically impact various pathophysiological situations, including fibrosis and cancer. Here, we uncover a novel paracrine effect of the SASP: the neuroendocrine transdifferentiation (NED) of some epithelial cancer cells, evidenced both in the breast and prostate. Mechanistically, this effect is mediated by NF-κB-dependent SASP factors, and leads to an increase in intracellular Ca2+ levels. Consistently, buffering Ca2+ by overexpressing the CALB1 buffering protein partly reverts SASP-induced NED, suggesting that the SASP promotes NED through a SASP-induced Ca2+ signaling. Human breast cancer dataset analyses support that NED occurs mainly in p53 WT tumors and in older patients, in line with a role of senescent cells and its secretome, as they are increasing during aging. In conclusion, our work, uncovering SASP-induced NED in some cancer cells, paves the way for future studies aiming at better understanding the functional link between senescent cell accumulation during aging, NED and clinical patient outcome.
Collapse
Affiliation(s)
- Clotilde Raynard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Xingjie Ma
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Department of Intensive CareThe Affiliated Hospital of Yangzhou University, Yangzhou UniversityYangzhouChina
| | - Anda Huna
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Nolwenn Tessier
- University of Lyon, CarMeN LaboratoryINSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1BronFrance
| | - Amélie Massemin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Kexin Zhu
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Jean‐Michel Flaman
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Florentin Moulin
- University of Lyon, CarMeN LaboratoryINSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1BronFrance
| | - Delphine Goehrig
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Jean‐Jacques Medard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Isabelle Treilleux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Hector Hernandez‐Vargas
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Sylvie Ducreux
- University of Lyon, CarMeN LaboratoryINSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1BronFrance
| | - Nadine Martin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| |
Collapse
|
6
|
Beaulieu D, Attwe A, Breau M, Lipskaia L, Marcos E, Born E, Huang J, Abid S, Derumeaux G, Houssaini A, Maitre B, Lefevre M, Vienney N, Bertolino P, Jaber S, Noureddine H, Goehrig D, Vindrieux D, Bernard D, Adnot S. Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease. Eur Respir J 2021; 58:13993003.00752-2020. [PMID: 33509955 DOI: 10.1183/13993003.00752-2020] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 12/28/2020] [Indexed: 01/08/2023]
Abstract
BACKGROUND Cell senescence is a key process in age-associated dysfunction and diseases, notably chronic obstructive pulmonary disease (COPD). We previously identified phospholipase A2 receptor 1 (PLA2R1) as a positive regulator of cell senescence acting via Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling. Its role in pathology, however, remains unknown. Here, we assessed PLA2R1-induced senescence in COPD and lung emphysema pathogenesis. METHODS We assessed cell senescence in lungs and cultured lung cells from patients with COPD and controls subjected to PLA2R1 knockdown, PLA2R1 gene transduction and treatment with the JAK1/2 inhibitor ruxolitinib. To assess whether PLA2R1 upregulation caused lung lesions, we developed transgenic mice overexpressing PLA2R1 (PLA2R1-TG) and intratracheally injected wild-type mice with a lentiviral vector carrying the Pla2r1 gene (LV-PLA2R1 mice). RESULTS We found that PLA2R1 was overexpressed in various cell types exhibiting senescence characteristics in COPD lungs. PLA2R1 knockdown extended the population doubling capacity of these cells and inhibited their pro-inflammatory senescence-associated secretory phenotype (SASP). PLA2R1-mediated cell senescence in COPD was largely reversed by treatment with the potent JAK1/2 inhibitor ruxolitinib. Five-month-old PLA2R1-TG mice exhibited lung cell senescence, and developed lung emphysema and lung fibrosis together with pulmonary hypertension. Treatment with ruxolitinib induced reversal of lung emphysema and fibrosis. LV-PLA2R1-treated mice developed lung emphysema within 4 weeks and this was markedly attenuated by concomitant ruxolitinib treatment. CONCLUSIONS Our data support a major role for PLA2R1 activation in driving lung cell senescence and lung alterations in COPD. Targeting JAK1/2 may represent a promising therapeutic approach for COPD.
Collapse
Affiliation(s)
- Delphine Beaulieu
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France.,These two authors contributed equally
| | - Aya Attwe
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France.,Environmental Health Research Laboratory (EHRL), Faculty of Sciences V, Lebanese University, Nabatieh, Lebanon.,These two authors contributed equally
| | - Marielle Breau
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Larissa Lipskaia
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Elisabeth Marcos
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Emmanuelle Born
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Jin Huang
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Shariq Abid
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Geneviève Derumeaux
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Amal Houssaini
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Bernard Maitre
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Marine Lefevre
- Département Anatomopathologie, Institut Mutualiste Montsouris, Paris, France
| | - Nora Vienney
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Philippe Bertolino
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052/CNRS 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Sara Jaber
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052/CNRS 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Hiba Noureddine
- Environmental Health Research Laboratory (EHRL), Faculty of Sciences V, Lebanese University, Nabatieh, Lebanon
| | - Delphine Goehrig
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052/CNRS 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052/CNRS 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052/CNRS 5286, Université de Lyon, Centre Léon Bérard, Lyon, France.,These two authors are joint senior authors
| | - Serge Adnot
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France .,Institute for Lung Health, University of Giessen, Giessen, Germany.,These two authors are joint senior authors
| |
Collapse
|
7
|
Huna A, Griveau A, Vindrieux D, Jaber S, Flaman JM, Goehrig D, Azzi L, Médard JJ, Djebali S, Hernandez-Vargas H, Dante R, Payen L, Marvel J, Bertolino P, Aubert S, Dubus P, Bernard D. PLA2R1 promotes DNA damage and inhibits spontaneous tumor formation during aging. Cell Death Dis 2021; 12:190. [PMID: 33594040 PMCID: PMC7887270 DOI: 10.1038/s41419-021-03468-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 01/16/2021] [Accepted: 01/21/2021] [Indexed: 02/07/2023]
Abstract
Although aging is a major risk factor for most types of cancers, it is barely studied in this context. The transmembrane protein PLA2R1 (phospholipase A2 receptor) promotes cellular senescence, which can inhibit oncogene-induced tumor initiation. Functions and mechanisms of action of PLA2R1 during aging are largely unknown. In this study, we observed that old Pla2r1 knockout mice were more prone to spontaneously develop a wide spectrum of tumors compared to control littermates. Consistently, these knockout mice displayed increased Parp1, a master regulator of DNA damage repair, and decreased DNA damage, correlating with large human dataset analysis. Forced PLA2R1 expression in normal human cells decreased PARP1 expression, induced DNA damage and subsequent senescence, while the constitutive expression of PARP1 rescued cells from these PLA2R1-induced effects. Mechanistically, PARP1 expression is repressed by a ROS (reactive oxygen species)-Rb-dependent mechanism upon PLA2R1 expression. In conclusion, our results suggest that PLA2R1 suppresses aging-induced tumors by repressing PARP1, via a ROS-Rb signaling axis, and inducing DNA damage and its tumor suppressive responses.
Collapse
Affiliation(s)
- Anda Huna
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Audrey Griveau
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Sara Jaber
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Jean-Michel Flaman
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Delphine Goehrig
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Lamia Azzi
- INSERM U1053 Bordeaux Research in Translational Oncology, University of Bordeaux, Bordeaux Cedex, France
| | - Jean-Jacques Médard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Sophia Djebali
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Hector Hernandez-Vargas
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Robert Dante
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Léa Payen
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Jacqueline Marvel
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Philippe Bertolino
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Sébastien Aubert
- Institut de Pathologie, Centre de Biologie Pathologie, CHRU de Lille, Faculté de Médecine, Université de Lille, Lille Cedex, France
| | - Pierre Dubus
- INSERM U1053 Bordeaux Research in Translational Oncology, University of Bordeaux, Bordeaux Cedex, France
- Plateau cellules tissus, CHU de Bordeaux, Pessac, France
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.
| |
Collapse
|
8
|
Ziegler DV, Vindrieux D, Goehrig D, Jaber S, Collin G, Griveau A, Wiel C, Bendridi N, Djebali S, Farfariello V, Prevarskaya N, Payen L, Marvel J, Aubert S, Flaman JM, Rieusset J, Martin N, Bernard D. Calcium channel ITPR2 and mitochondria-ER contacts promote cellular senescence and aging. Nat Commun 2021; 12:720. [PMID: 33526781 PMCID: PMC7851384 DOI: 10.1038/s41467-021-20993-z] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Accepted: 12/15/2020] [Indexed: 12/29/2022] Open
Abstract
Cellular senescence is induced by stresses and results in a stable proliferation arrest accompanied by a pro-inflammatory secretome. Senescent cells accumulate during aging, promoting various age-related pathologies and limiting lifespan. The endoplasmic reticulum (ER) inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) calcium-release channel and calcium fluxes from the ER to the mitochondria are drivers of senescence in human cells. Here we show that Itpr2 knockout (KO) mice display improved aging such as increased lifespan, a better response to metabolic stress, less immunosenescence, as well as less liver steatosis and fibrosis. Cellular senescence, which is known to promote these alterations, is decreased in Itpr2 KO mice and Itpr2 KO embryo-derived cells. Interestingly, ablation of ITPR2 in vivo and in vitro decreases the number of contacts between the mitochondria and the ER and their forced contacts induce premature senescence. These findings shed light on the role of contacts and facilitated exchanges between the ER and the mitochondria through ITPR2 in regulating senescence and aging.
Collapse
Affiliation(s)
- Dorian V Ziegler
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Delphine Goehrig
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Sara Jaber
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Guillaume Collin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Audrey Griveau
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Clotilde Wiel
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Nadia Bendridi
- CarMeN Laboratory, INSERM UMR-1060, Lyon 1 University, INRA U1397, F-69921, Oullins, France
| | - Sophia Djebali
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Valerio Farfariello
- INSERM U1003, Laboratoire d'Excellence, Canaux Ioniques d'Intérêt Thérapeutique, Équipe Labellisée Par la Ligue Nationale Contre le Cancer, SIRIC ONCOLille, Université des Sciences et Technologies de Lille, Villeneuve d'Ascq, France
| | - Natacha Prevarskaya
- INSERM U1003, Laboratoire d'Excellence, Canaux Ioniques d'Intérêt Thérapeutique, Équipe Labellisée Par la Ligue Nationale Contre le Cancer, SIRIC ONCOLille, Université des Sciences et Technologies de Lille, Villeneuve d'Ascq, France
| | - Léa Payen
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Jacqueline Marvel
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Sébastien Aubert
- Institut de Pathologie, Centre de Biologie Pathologie, CHRU de Lille, Faculté de Médecine, Université de Lille, Lille Cedex, France
| | - Jean-Michel Flaman
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - Jennifer Rieusset
- CarMeN Laboratory, INSERM UMR-1060, Lyon 1 University, INRA U1397, F-69921, Oullins, France
| | - Nadine Martin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.
| |
Collapse
|
9
|
Griveau A, Wiel C, Le Calvé B, Ziegler DV, Djebali S, Warnier M, Martin N, Marvel J, Vindrieux D, Bergo MO, Bernard D. Targeting the phospholipase A2 receptor ameliorates premature aging phenotypes. Aging Cell 2018; 17:e12835. [PMID: 30216637 PMCID: PMC6260922 DOI: 10.1111/acel.12835] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 07/13/2018] [Accepted: 07/29/2018] [Indexed: 11/26/2022] Open
Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is a lethal premature aging that recapitulates many normal aging characteristics. This disorder is caused by mutation in the LMNA gene leading to the production of progerin which induces misshapen nuclei, cellular senescence, and aging. We previously showed that the phospholipase A2 receptor (PLA2R1) promotes senescence induced by replicative, oxidative, and oncogenic stress but its role during progerin‐induced senescence and in progeria is currently unknown. Here, we show that knockdown of PLA2R1 prevented senescence induced by progerin expression in human fibroblasts and markedly delayed senescence of HGPS patient‐derived fibroblasts. Whole‐body knockout of Pla2r1 in a mouse model of progeria decreased some premature aging phenotypes, such as rib fracture and decreased bone content, together with decreased senescence marker. Progerin‐expressing human fibroblasts exhibited a high frequency of misshapen nuclei and increased farnesyl diphosphate synthase (FDPS) expression compared to controls; knockdown of PLA2R1 reduced the frequency of misshapen nuclei and normalized FDPS expression. Pamidronate, a FDPS inhibitor, also reduced senescence and misshapen nuclei. Downstream of PLA2R1, we found that p53 mediated the progerin‐induced increase in FDPS expression and in misshapen nuclei. These results suggest that PLA2R1 mediates key premature aging phenotypes through a p53/FDPS pathway and might be a new therapeutic target.
Collapse
Affiliation(s)
- Audrey Griveau
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard; Université de Lyon; Lyon France
| | - Clotilde Wiel
- Department of Biosciences and Nutrition; Karolinska Institutet; Huddinge Sweden
| | - Benjamin Le Calvé
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard; Université de Lyon; Lyon France
| | - Dorian V. Ziegler
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard; Université de Lyon; Lyon France
| | - Sophia Djebali
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS, UMR5308, École Normale Supérieure de Lyon; Université de Lyon; Université Claude Bernard Lyon 1; Lyon France
| | - Marine Warnier
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard; Université de Lyon; Lyon France
| | - Nadine Martin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard; Université de Lyon; Lyon France
| | - Jacqueline Marvel
- Centre International de Recherche en Infectiologie, Inserm U1111, CNRS, UMR5308, École Normale Supérieure de Lyon; Université de Lyon; Université Claude Bernard Lyon 1; Lyon France
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard; Université de Lyon; Lyon France
| | - Martin O. Bergo
- Department of Biosciences and Nutrition; Karolinska Institutet; Huddinge Sweden
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard; Université de Lyon; Lyon France
| |
Collapse
|
10
|
Warnier M, Flaman JM, Chouabe C, Wiel C, Gras B, Griveau A, Blanc E, Foy JP, Mathot P, Saintigny P, Van Coppenolle F, Vindrieux D, Martin N, Bernard D. The SCN9A channel and plasma membrane depolarization promote cellular senescence through Rb pathway. Aging Cell 2018; 17:e12736. [PMID: 29446526 PMCID: PMC5946064 DOI: 10.1111/acel.12736] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/29/2017] [Indexed: 12/15/2022] Open
Abstract
Oncogenic signals lead to premature senescence in normal human cells causing a proliferation arrest and the elimination of these defective cells by immune cells. Oncogene‐induced senescence (OIS) prevents aberrant cell division and tumor initiation. In order to identify new regulators of OIS, we performed a loss‐of‐function genetic screen and identified that the loss of SCN9A allowed cells to escape from OIS. The expression of this sodium channel increased in senescent cells during OIS. This upregulation was mediated by NF‐κB transcription factors, which are well‐known regulators of senescence. Importantly, the induction of SCN9A by an oncogenic signal or by p53 activation led to plasma membrane depolarization, which in turn, was able to induce premature senescence. Computational and experimental analyses revealed that SCN9A and plasma membrane depolarization mediated the repression of mitotic genes through a calcium/Rb/E2F pathway to promote senescence. Taken together, our work delineates a new pathway, which involves the NF‐κB transcription factor, SCN9A expression, plasma membrane depolarization, increased calcium, the Rb/E2F pathway and mitotic gene repression in the regulation of senescence. This work thus provides new insight into the involvement of ion channels and plasma membrane potential in the control of senescence.
Collapse
Affiliation(s)
- Marine Warnier
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Jean-Michel Flaman
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Christophe Chouabe
- Inserm UMR-U1060 CarMeN Laboratory; INRA U1235, INSA-Lyon; Facultés de médecine Rockefeller; University Lyon 1; Lyon France
| | - Clotilde Wiel
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Baptiste Gras
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Audrey Griveau
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Elena Blanc
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Jean-Philippe Foy
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Pauline Mathot
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Pierre Saintigny
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Fabien Van Coppenolle
- Inserm UMR-U1060 CarMeN Laboratory; INRA U1235, INSA-Lyon; Facultés de médecine Rockefeller; University Lyon 1; Lyon France
| | - David Vindrieux
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - Nadine Martin
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| | - David Bernard
- Inserm U1052, CNRS UMR 5286; Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon; Lyon France
| |
Collapse
|
11
|
Houssaini A, Breau M, Kebe K, Abid S, Marcos E, Lipskaia L, Rideau D, Parpaleix A, Huang J, Amsellem V, Vienney N, Validire P, Maitre B, Attwe A, Lukas C, Vindrieux D, Boczkowski J, Derumeaux G, Pende M, Bernard D, Meiners S, Adnot S. mTOR pathway activation drives lung cell senescence and emphysema. JCI Insight 2018; 3:93203. [PMID: 29415880 DOI: 10.1172/jci.insight.93203] [Citation(s) in RCA: 112] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 01/05/2018] [Indexed: 01/07/2023] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a highly prevalent and devastating condition for which no curative treatment is available. Exaggerated lung cell senescence may be a major pathogenic factor. Here, we investigated the potential role for mTOR signaling in lung cell senescence and alterations in COPD using lung tissue and derived cultured cells from patients with COPD and from age- and sex-matched control smokers. Cell senescence in COPD was linked to mTOR activation, and mTOR inhibition by low-dose rapamycin prevented cell senescence and inhibited the proinflammatory senescence-associated secretory phenotype. To explore whether mTOR activation was a causal pathogenic factor, we developed transgenic mice exhibiting mTOR overactivity in lung vascular cells or alveolar epithelial cells. In this model, mTOR activation was sufficient to induce lung cell senescence and to mimic COPD lung alterations, with the rapid development of lung emphysema, pulmonary hypertension, and inflammation. These findings support a causal relationship between mTOR activation, lung cell senescence, and lung alterations in COPD, thereby identifying the mTOR pathway as a potentially new therapeutic target in COPD.
Collapse
Affiliation(s)
- Amal Houssaini
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France.,Comprehensive Pneumology Center (CPC), University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Marielle Breau
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Kanny Kebe
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Shariq Abid
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Elisabeth Marcos
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Larissa Lipskaia
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Dominique Rideau
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Aurelien Parpaleix
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Jin Huang
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Valerie Amsellem
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Nora Vienney
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Pierre Validire
- Institut Mutualiste Montsouris, Département anatomopathologie, Paris, France
| | - Bernard Maitre
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Aya Attwe
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Christina Lukas
- Comprehensive Pneumology Center (CPC), University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052/CNRS 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Jorge Boczkowski
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Genevieve Derumeaux
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Mario Pende
- INSERM U845, Université Paris Descartes, 75015, Paris, France
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052/CNRS 5286, Université de Lyon, Centre Léon Bérard, Lyon, France
| | - Silke Meiners
- Comprehensive Pneumology Center (CPC), University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Serge Adnot
- INSERM U955, Département de Physiologie-Explorations Fonctionnelles, and DHU A-TVB Hôpital Henri Mondor, AP-HP, Créteil, France
| |
Collapse
|
12
|
Ferrand M, Kirsh O, Griveau A, Vindrieux D, Martin N, Defossez PA, Bernard D. Screening of a kinase library reveals novel pro-senescence kinases and their common NF-κB-dependent transcriptional program. Aging (Albany NY) 2016; 7:986-1003. [PMID: 26583757 PMCID: PMC4694068 DOI: 10.18632/aging.100845] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Cellular senescence results in proliferation arrest and acquisition of hallmarks such as the Senescence-Associated Secretory Phenotype (SASP). Senescence is involved in regulating numerous physio-pathological responses, including embryonic development, cancer, and several aging-related diseases. Only a few kinases, centered on the RAS signaling pathway, have been identified as inducing premature senescence. About possible other senescence-regulating kinases and signaling pathways, practically little is known. By screening a library of activated kinases, we identified 33 kinases whose constitutive expression decreases cell proliferation and induces expression of senescence markers; p16 and SASP components. Focusing on some kinases showing the strongest pro-senescence effects, we observed that they all induce expression of SASP-component genes through activation of an NF-κB-dependent transcriptional program. Furthermore, inhibition of the p53 or Rb pathway failed to prevent the SASP-inducing effect of pro-senescence kinases. Inhibition of the NF-κB, p53, or Rb pathway proved insufficient to prevent kinase-triggered cell cycle arrest. We have thus identified a repertoire of novel pro-senescence kinases and pathways. These results will open new perspectives in the understanding on the role of cellular senescence in various physio-pathological responses.
Collapse
Affiliation(s)
- Mylène Ferrand
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69373 Lyon, France.,CNRS UMR 5286, F-69373 Lyon, France.,Centre Léon Bérard, F-69373 Lyon, France.,Université de Lyon, F-69373 Lyon, France
| | - Olivier Kirsh
- Epigenetics and Cell Fate, University Paris Diderot, Sorbonne Paris Cité, UMR 7216 CNRS, 75013 Paris, France
| | - Audrey Griveau
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69373 Lyon, France.,CNRS UMR 5286, F-69373 Lyon, France.,Centre Léon Bérard, F-69373 Lyon, France.,Université de Lyon, F-69373 Lyon, France
| | - David Vindrieux
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69373 Lyon, France.,CNRS UMR 5286, F-69373 Lyon, France.,Centre Léon Bérard, F-69373 Lyon, France.,Université de Lyon, F-69373 Lyon, France
| | - Nadine Martin
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69373 Lyon, France.,CNRS UMR 5286, F-69373 Lyon, France.,Centre Léon Bérard, F-69373 Lyon, France.,Université de Lyon, F-69373 Lyon, France
| | - Pierre-Antoine Defossez
- Epigenetics and Cell Fate, University Paris Diderot, Sorbonne Paris Cité, UMR 7216 CNRS, 75013 Paris, France
| | - David Bernard
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69373 Lyon, France.,CNRS UMR 5286, F-69373 Lyon, France.,Centre Léon Bérard, F-69373 Lyon, France.,Université de Lyon, F-69373 Lyon, France
| |
Collapse
|
13
|
Griveau A, Devailly G, Eberst L, Navaratnam N, Le Calvé B, Ferrand M, Faull P, Augert A, Dante R, Vanacker JM, Vindrieux D, Bernard D. The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action. Oncogene 2016; 35:5033-42. [PMID: 27041564 DOI: 10.1038/onc.2016.43] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 01/06/2016] [Accepted: 02/08/2016] [Indexed: 12/20/2022]
Abstract
Little is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein. In recent years, PLA2R1 has been shown to have an important role in regulating tumor-suppressive responses via JAK2 activation, but the underlying mechanisms are largely undeciphered. In this study, we observed that PLA2R1 increases the mitochondrial content, judged by increased levels of numerous mitochondrial proteins, of the mitochondrial structural component cardiolipin, of the mitochondrial DNA content, and of the mitochondrial DNA replication and transcription factor TFAM. This effect of PLA2R1 relies on a transcriptional program controlled by the estrogen-related receptor alpha1 (ERRα) mitochondrial master regulator. Expression of ERRα and of its nucleus-encoded mitochondrial targets is upregulated upon PLA2R1 ectopic expression, and this effect is mediated by JAK2. Conversely, downregulation of PLA2R1 decreases the level of ERRα and of its nucleus-encoded mitochondrial targets. Finally, blocking the ERRα-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERRα and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression.
Collapse
Affiliation(s)
- A Griveau
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - G Devailly
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - L Eberst
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - N Navaratnam
- Cellular Stress Group, MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Campus, London, UK
| | - B Le Calvé
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - M Ferrand
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - P Faull
- Biological Mass Spectrometry and Proteomics Laboratory, MRC Clinical Sciences Centre, Imperial College London, London, UK
| | - A Augert
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - R Dante
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - J M Vanacker
- Institut de Génomique Fonctionnelle de Lyon, Université de Lyon, Université Lyon I, CNRS UMR5242, Ecole Normale Supérieure de Lyon, Lyon, France
| | - D Vindrieux
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| | - D Bernard
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- CNRS UMR 5286, Lyon, France
- Centre Léon Bérard, Lyon, France
- Université de Lyon, Lyon, France
| |
Collapse
|
14
|
Wiel C, Gras B, Vindrieux D, Warnier M, Gitenay D, Le Calvé B, Ferrand M, Augert A, Bernard D. Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape. Oncogene 2015; 35:1596-601. [PMID: 26073088 DOI: 10.1038/onc.2015.218] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Revised: 04/22/2015] [Accepted: 04/24/2015] [Indexed: 02/07/2023]
Abstract
Oncogenic-stress-induced senescence (OIS) is a stress response allowing normal cells, when receiving oncogenic signals, to stably arrest their proliferation. OIS thus acts to prevent aberrant cell proliferation and tumor formation. To identify novel tumor suppressive pathways, we have recently completed a loss-of-function genetic screen to identify novel genes promoting escape from OIS and thus, potentially, tumor formation when their functions are lost. Using this approach, we unexpectedly found that loss of function of the multidrug resistance protein 3 (MRP3 or ABCC3) promotes escape from OIS in human epithelial cells. Importantly, ABCC3 expression is reduced in human skin tumors, and ABCC3-knockout mice display increased sensitivity to RAS-induced skin carcinogenesis, concomitantly with decreased OIS. ABCC3 participates in resistance to chemotherapy via its transporter activity. Our data show that this transporter activity is involved in ABCC3-induced senescence, demonstrating that this protein has a complex role in cancer, since its loss of function may promote escape from OIS and tumor formation whereas its gain of function promotes resistance to chemotherapy.
Collapse
Affiliation(s)
- C Wiel
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - B Gras
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - D Vindrieux
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - M Warnier
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - D Gitenay
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - B Le Calvé
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - M Ferrand
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - A Augert
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| | - D Bernard
- Senescence Escape Mechanisms Laboratory, Tumoral Escape Department, Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.,CNRS UMR5286, Lyon, France.,Centre Léon Bérard, Lyon, France.,Université de Lyon, Lyon, France
| |
Collapse
|
15
|
Vindrieux D, Devailly G, Augert A, Le Calvé B, Ferrand M, Pigny P, Payen L, Lambeau G, Perrais M, Aubert S, Simonnet H, Dante R, Bernard D. Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth. Oncotarget 2015; 5:1004-13. [PMID: 24657971 PMCID: PMC4011578 DOI: 10.18632/oncotarget.1681] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Loss of secreted phospholipase A2 receptor (PLA2R1) has recently been found to render human primary cells more resistant to senescence whereas increased PLA2R1 expression is able to induce cell cycle arrest, cancer cell death or blockage of cancer cell transformation in vitro, suggesting that PLA2R1 displays tumor suppressive activities. Here we report that PLA2R1 expression strongly decreases in samples of human renal cell carcinoma (RCC). Knockdown of PLA2R1 increases renal cancer cell tumorigenicity supporting a role of PLA2R1 loss to promote in vivo RCC growth. Most RCC result from Von Hippel-Lindau (VHL) tumor suppressor loss-of-function and subsequent gain-of-function of the oncogenic HIF-2alpha/c-MYC pathway. Here, by genetically manipulating VHL, HIF-2alpha and c-MYC, we demonstrate that loss of VHL, stabilization of HIF-2alpha and subsequent increased c-MYC activity, binding and transcriptional repression, through induction of PLA2R1 DNA methylation closed to PLA2R1 transcriptional start site, results in decreased PLA2R1 transcription. Our results describe for the first time an oncogenic pathway leading to PLA2R1 transcriptional repression and the importance of this repression for tumor growth.
Collapse
Affiliation(s)
- David Vindrieux
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Girard CA, Seitz-Polski B, Dolla G, Augert A, Vindrieux D, Bernard D, Lambeau G. Nouveaux rôles physiopathologiques pour le récepteur PLA2R1 dans le cancer et la glomérulonéphrite extramembraneuse. Med Sci (Paris) 2014; 30:519-25. [DOI: 10.1051/medsci/20143005014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
|
17
|
Wiel C, Lallet-Daher H, Gitenay D, Gras B, Le Calvé B, Augert A, Ferrand M, Prevarskaya N, Simonnet H, Vindrieux D, Bernard D. Endoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence. Nat Commun 2014; 5:3792. [DOI: 10.1038/ncomms4792] [Citation(s) in RCA: 109] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Accepted: 04/03/2014] [Indexed: 12/21/2022] Open
|
18
|
Abstract
The phospholipase A2 receptor 1 (PLA2R1 or PLA2R) was isolated twenty years ago for its ability to bind several secretory phospholipase A2 proteins (sPLA2). Since its identification, it has attracted only a limited interest, mainly in the sPLA2 biology field, as it is viewed uniquely as a regulator of sPLA2 activities. Recent discoveries outline novel important functions of this gene in cancer biology. Indeed, PLA2R1 gain or loss of function experiments in vitro and in vivo shows that this receptor promotes several tumor suppressive responses including senescence, apoptosis and inhibition of transformation. Supporting a tumor suppressive role of PLA2R1, its expression decreases in numerous cancers, and known oncogenes such as HIF2α and c-MYC repress its expression. PLA2R1 promoter methylation, a classical way to repress tumor suppressive gene expression in cancer cells, is observed in leukemia, in kidney and in breast cancer cells. Mechanistically, PLA2R1 activates the kinase JAK2 and orients its activity towards a tumor suppressive one. PLA2R1 also promotes accumulation of reactive oxygen species which induce cell death and senescence. This review compiles recent data demonstrating an unexpected tumor suppressive role of PLA2R1 and outlines the future work needed to improve our knowledge of the functions of this gene in cancer.
Collapse
Affiliation(s)
- David Bernard
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR 5286, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France.
| | - David Vindrieux
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR 5286, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| |
Collapse
|
19
|
Augert A, Vindrieux D, Girard CA, Le Calvé B, Gras B, Ferrand M, Bouchet BP, Puisieux A, de Launoit Y, Simonnet H, Lambeau G, Bernard D. PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med 2013; 65:969-977. [PMID: 23994771 DOI: 10.1016/j.freeradbiomed.2013.08.177] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Revised: 08/19/2013] [Accepted: 08/22/2013] [Indexed: 12/17/2022]
Abstract
Little is known about the biological functions of the phospholipase A2 receptor (PLA2R1) except that it has the ability to bind a few secreted phospholipases A2 (sPLA2's). We have previously shown that PLA2R1 regulates senescence in normal human cells. In this study, we investigated the ability of PLA2R1 to control cancer cell growth. Analysis of expression in cancer cells indicates a marked PLA2R1 decrease in breast cancer cell lines compared to normal or nontransformed human mammary epithelial cells. Accordingly, PLA2R1 ectopic expression in PLA2R1-negative breast cancer cell lines led to apoptosis, whereas a prosenescence response was predominantly triggered in normal cells. PLA2R1 structure-function studies and the use of chemical inhibitors of sPLA2-related signaling pathways suggest that the effect of PLA2R1 is sPLA2-independent. Functional experiments demonstrate that PLA2R1 regulation of cell death is driven by a reactive oxygen species (ROS)-dependent mechanism. While screening for ROS-producing complexes involved in PLA2R1 biological responses, we identified a critical role for the mitochondrial electron transport chain in PLA2R1-induced ROS production and cell death. Taken together, this set of data provides evidence for an important role of PLA2R1 in controlling cancer cell death by influencing mitochondrial biology.
Collapse
Affiliation(s)
- Arnaud Augert
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France; UMR8161, Institut de Biologie de Lille, CNRS/Universités de Lille 1 et 2, Lille F-5900, France
| | - David Vindrieux
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| | - Christophe A Girard
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, CNRS, and Université de Nice-Sophia Antipolis, Valbonne F-06560, France
| | - Benjamin Le Calvé
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| | - Baptiste Gras
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| | - Mylène Ferrand
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| | - Benjamin P Bouchet
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| | - Alain Puisieux
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| | - Yvan de Launoit
- UMR8161, Institut de Biologie de Lille, CNRS/Universités de Lille 1 et 2, Lille F-5900, France
| | - Hélène Simonnet
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France
| | - Gérard Lambeau
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, CNRS, and Université de Nice-Sophia Antipolis, Valbonne F-06560, France
| | - David Bernard
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon F-69373, France; Centre Léon Bérard, Lyon F-69373, France; Université de Lyon, Lyon F-69373, France.
| |
Collapse
|
20
|
Vindrieux D, Gras B, Garcia-Belinchon M, Mourah S, Lebbe C, Augert A, Bernard D. Platelet-derived growth factor B induces senescence and transformation in normal human fibroblasts. Aging (Albany NY) 2013; 5:531-8. [PMID: 23934686 PMCID: PMC3765581 DOI: 10.18632/aging.100577] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Normal cells enter a senescent state upon aberrant oncogenic signals and this response inhibits tumor initiation and progression. It is now well admitted that intracellular and membrane localized oncogenes can illicit oncogene induced senescence. However, the effect of mitogenic growth factor on cellular senescence is so far largely unknown. Here we show that normal human dermal fibroblasts display a complex response to Platelet derived growth factor B (PDGFB) expression. Indeed, PDGFB expression induces, in the same cell population, both senescence and cellular transformation. Remarkably both populations are sustained with passages suggesting that transformed cells eventually enter a senescent state. This senescence state is p53 dependent as inhibiting the p53 pathway blocks the ability of PDGFB to induce senescence and results in strong cellular transformation increase upon PDGFB expression. The relevance of these observations is supported by the fact that human dermatofibrosarcoma protuberans, skin tumors arising from constitutive PDGFB production with little aggressiveness, also display some senescence hallmarks. Together these data support the view that PDGFB, a mitogenic growth factor, has a limited ability to induce senescence. We propose that this low level of senescence might decrease the transforming ability of this factor without totally abolishing it.
Collapse
Affiliation(s)
- David Vindrieux
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France
| | | | | | | | | | | | | |
Collapse
|
21
|
Wiel C, Augert A, Vincent DF, Gitenay D, Vindrieux D, Le Calvé B, Arfi V, Lallet-Daher H, Reynaud C, Treilleux I, Bartholin L, Lelievre E, Bernard D. Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis. Cell Death Dis 2013; 4:e855. [PMID: 24113189 PMCID: PMC3824691 DOI: 10.1038/cddis.2013.382] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Revised: 09/03/2013] [Accepted: 09/03/2013] [Indexed: 12/23/2022]
Abstract
Cellular senescence, a stable proliferation arrest, is induced in response to various stresses. Oncogenic stress-induced senescence (OIS) results in blocked proliferation and constitutes a fail-safe program counteracting tumorigenesis. The events that enable a tumor in a benign senescent state to escape from OIS and become malignant are largely unknown. We show that lysyl oxidase activity contributes to the decision to maintain senescence. Indeed, in human epithelial cell the constitutive expression of the LOX or LOXL2 protein favored OIS escape, whereas inhibition of lysyl oxidase activity was found to stabilize OIS. The relevance of these in vitro observations is supported by in vivo findings: in a transgenic mouse model of aggressive pancreatic ductal adenocarcinoma (PDAC), increasing lysyl oxidase activity accelerates senescence escape, whereas inhibition of lysyl oxidase activity was found to stabilize senescence, delay tumorigenesis, and increase survival. Mechanistically, we show that lysyl oxidase activity favors the escape of senescence by regulating the focal-adhesion kinase. Altogether, our results demonstrate that lysyl oxidase activity participates in primary tumor growth by directly impacting the senescence stability.
Collapse
Affiliation(s)
- C Wiel
- 1] Inserm U1052, Centre de Recherche en Cancérologie de Lyon [2] CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon [3] Centre Léon Bérard [4] Université de Lyon, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Vindrieux D, Augert A, Girard CA, Gitenay D, Lallet-Daher H, Wiel C, Le Calvé B, Gras B, Ferrand M, Verbeke S, de Launoit Y, Leroy X, Puisieux A, Aubert S, Perrais M, Gelb M, Simonnet H, Lambeau G, Bernard D. PLA2R1 Mediates Tumor Suppression by Activating JAK2. Cancer Res 2013; 73:6334-45. [DOI: 10.1158/0008-5472.can-13-0318] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Lallet-Daher H, Wiel C, Gitenay D, Navaratnam N, Augert A, Le Calvé B, Verbeke S, Carling D, Aubert S, Vindrieux D, Bernard D. Potassium Channel KCNA1 Modulates Oncogene-Induced Senescence and Transformation. Cancer Res 2013; 73:5253-65. [DOI: 10.1158/0008-5472.can-12-3690] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, Jacquard C, Pillon A, Balaguer P, Balabanian K, Lazennec G. Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One 2012; 7:e44787. [PMID: 22970307 PMCID: PMC3435304 DOI: 10.1371/journal.pone.0044787] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2011] [Accepted: 08/13/2012] [Indexed: 11/28/2022] Open
Abstract
Ovarian cancer is the gynecological cancer exhibiting the highest morbidity and improvement of treatments is still required. Previous studies have shown that Estrogen-receptor beta (ERβ) levels decreased along with ovarian carcinogenesis. Here, we present evidence that reintroduction of ERβ in BG-1 epithelial ovarian cancer cells, which express ERα, leads in vitro to a decrease of basal and estradiol-promoted cell proliferation. ERβ reduced the frequency of cells in S phase and increased the one of cells in G2/M phase. At the molecular level, we found that ERβ downregulated total retinoblastoma (Rb), phosphorylated Rb and phospho-AKT cellular content as well as cyclins D1 and A2. In addition, ERβ had a direct effect on ERα, by strongly inhibiting its expression and activity, which could explain part of the anti-proliferative action of ERβ. By developing a novel preclinical model of ovarian cancer based on a luminescent orthotopic xenograft in athymic Nude mice, we further revealed that ERβ expression reduces tumor growth and the presence of tumor cells in sites of metastasis, hence resulting in improved survival of mice. Altogether, these findings unveil a potential tumor-suppressor role of ERβ in ovarian carcinogenesis, which could be of potential clinical relevance for the selection of the most appropriate treatment for patients.
Collapse
Affiliation(s)
- Carine Bossard
- Institut National de la Santé et de la Recherche Médicale (INSERM), U844, University of Montpellier I, Montpellier, F-34091, France
| | - Muriel Busson
- Institut National de la Santé et de la Recherche Médicale (INSERM), U844, University of Montpellier I, Montpellier, F-34091, France
| | - David Vindrieux
- Institut National de la Santé et de la Recherche Médicale (INSERM), U844, University of Montpellier I, Montpellier, F-34091, France
| | - Françoise Gaudin
- Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT), Institut National de la Santé et de la Recherche Médicale (INSERM), UMR_S996, Univ. Paris-Sud, Clamart, France
| | - Véronique Machelon
- Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT), Institut National de la Santé et de la Recherche Médicale (INSERM), UMR_S996, Univ. Paris-Sud, Clamart, France
| | - Madly Brigitte
- Institut National de la Santé et de la Recherche Médicale (INSERM), U844, University of Montpellier I, Montpellier, F-34091, France
| | - Carine Jacquard
- Institut National de la Santé et de la Recherche Médicale (INSERM), U844, University of Montpellier I, Montpellier, F-34091, France
| | - Arnaud Pillon
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, France
| | - Patrick Balaguer
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, France
| | - Karl Balabanian
- Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT), Institut National de la Santé et de la Recherche Médicale (INSERM), UMR_S996, Univ. Paris-Sud, Clamart, France
| | - Gwendal Lazennec
- Institut National de la Santé et de la Recherche Médicale (INSERM), U844, University of Montpellier I, Montpellier, F-34091, France
- * E-mail:
| |
Collapse
|
25
|
Vindrieux D, Réveiller M, Chantepie J, Yakoub S, Deschildre C, Ruffion A, Devonec M, Benahmed M, Grataroli R. Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int 2011; 11:42. [PMID: 22136382 PMCID: PMC3286382 DOI: 10.1186/1475-2867-11-42] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2011] [Accepted: 12/02/2011] [Indexed: 12/11/2022] Open
Abstract
Background Dysregulation of many apoptotic related genes and androgens are critical in the development, progression, and treatment of prostate cancer. The differential sensitivity of tumour cells to TRAIL-induced apoptosis can be mediated by the modulation of surface TRAIL receptor expression related to androgen concentration. Our previous results led to the hypothesis that downregulation of TRAIL-decoy receptor DcR2 expression following androgen deprivation would leave hormone sensitive normal prostate cells vulnerable to the cell death signal generated by TRAIL via its pro-apoptotic receptors. We tested this hypothesis under pathological conditions by exploring the regulation of TRAIL-induced apoptosis related to their death and decoy receptor expression, as also to hormonal concentrations in androgen-sensitive human prostate cancer, LNCaP, cells. Results In contrast to androgen-insensitive PC3 cells, decoy (DcR2) and death (DR5) receptor protein expression was correlated with hormone concentrations and TRAIL-induced apoptosis in LNCaP cells. Silencing of androgen-sensitive DcR2 protein expression by siRNA led to a significant increase in TRAIL-mediated apoptosis related to androgen concentration in LNCaP cells. Conclusions The data support the hypothesis that hormone modulation of DcR2 expression regulates TRAIL-induced apoptosis in LNCaP cells, giving insight into cell death induction in apoptosis-resistant hormone-sensitive tumour cells from prostate cancer. TRAIL action and DcR2 expression modulation are potentially of clinical value in advanced tumour treatment.
Collapse
Affiliation(s)
- David Vindrieux
- UMR Inserm U1052/CNRS 5286, Centre Léon Bérard, 28 rue Laënnec, 69373 Lyon Cedex 08, France
| | - Marie Réveiller
- NYU Langone Medical Center, Department of Medicine and Pathology, 423 East 23 rd street, New York, NY 10010, USA
| | | | - Sadok Yakoub
- Unité de nutrition humaine, UMR INRA U1019/Université Clermont 1, Centre de recherche INRA de Clermont-Ferrand/Theix, 63122 St Genès Champanelle, France
| | - Catherine Deschildre
- U851 Inserm-UCBL-HCL, Tour INSERM CERVI, 21 avenue Tony Garnier, 69365 Lyon, France
| | - Alain Ruffion
- Service d'Urologie, Centre Hospitalier Lyon Sud, 165 chemin du grand Revoyet, 69921 Oullins, France
| | - Marian Devonec
- Service d'Urologie, Centre Hospitalier Lyon Sud, 165 chemin du grand Revoyet, 69921 Oullins, France
| | - Mohamed Benahmed
- U895 Inserm, Université de Nice-Sophia Antipolis, UFR Medecine, 151 route Saint Antoine de Ginestiere, 06204 Nice, France
| | - Renée Grataroli
- SF Biosciences Gerland-Lyon Sud, CNRS UMS3444/Inserm US8, Université Claude Bernard Lyon 1, 50 avenue Tony Garnier, 69366 Lyon, France
| |
Collapse
|
26
|
Vindrieux D, Le Corre L, Hsieh JT, Métivier R, Escobar P, Caicedo A, Brigitte M, Lazennec G. Coxsackie and adenovirus receptor is a target and a mediator of estrogen action in breast cancer. Endocr Relat Cancer 2011; 18:311-21. [PMID: 21389059 DOI: 10.1530/erc-10-0230] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The involvement of the coxsackie and adenovirus receptor (CAR), an adhesion molecule known to be the main determinant of adenovirus transduction of the cells, in cancer is currently under investigation. Recent reports suggest that CAR levels are elevated in breast cancer, and this may have an impact on its use as means of delivery for gene therapy. In this study, we show that estradiol (E(2)) treatment of the estrogen receptor (ER)-positive breast cancer cell MCF-7 increases CAR levels and, in turn, enhances adenoviral transduction. Employing the transfection of CAR promoters in breast cancer cells, we show that this regulation of CAR expression occurs at the transcriptional level. In addition, and by chromatin immunoprecipitation, we have identified a crucial region of CAR promoter that controls E(2) responsiveness of CAR gene through the recruitment of ER. Moreover, utilizing CAR antibodies or CAR silencing by RNA interference repressed the estrogen-dependent growth of breast cancer cells, whereas the stable expression of CAR in MCF-7 or MDA-MB-231 cells led to an increased proliferation. Altogether, our data suggest that CAR is a novel estrogen-responsive gene, which is involved in the E(2)-dependent proliferation of breast cancer cells.
Collapse
MESH Headings
- Adenocarcinoma/metabolism
- Adenocarcinoma/pathology
- Adenoviruses, Human/physiology
- Antibodies, Monoclonal/pharmacology
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Cell Division/drug effects
- Cell Line, Tumor/drug effects
- Cell Line, Tumor/metabolism
- Coxsackie and Adenovirus Receptor-Like Membrane Protein
- Estradiol/pharmacology
- Estrogen Receptor alpha/drug effects
- Estrogen Receptor alpha/genetics
- Estrogens/physiology
- Female
- Genes, Reporter
- Humans
- Mutagenesis, Site-Directed
- Neoplasm Proteins/antagonists & inhibitors
- Neoplasm Proteins/drug effects
- Neoplasm Proteins/genetics
- Neoplasm Proteins/physiology
- Neoplasms, Hormone-Dependent/metabolism
- Neoplasms, Hormone-Dependent/pathology
- Promoter Regions, Genetic/drug effects
- RNA Interference
- RNA, Neoplasm/biosynthesis
- RNA, Small Interfering/pharmacology
- Receptors, Virus/antagonists & inhibitors
- Receptors, Virus/drug effects
- Receptors, Virus/genetics
- Receptors, Virus/physiology
- Recombinant Fusion Proteins/physiology
- Signal Transduction
- Transcription, Genetic
- Transfection
Collapse
Affiliation(s)
- David Vindrieux
- INSERM, U844, Hôpital Saint Eloi, Montpellier F-34091, France
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Prostate cancer (PCa) represents the second leading cause of death among all cancer types in men in Europe and North America. Among the factors suspected to control PCa, incidence and progression, chemokines, and their receptors are now intensively studied. Chemokines are produced by tumor cells and also by the stromal microenvironment, both in the primary tumor site and in distant metastatic locations. The wide and differential distribution of chemokines and their receptors account for the pleiotropic actions of chemokines in PCa, including the modulation of growth, angiogenesis, invasion, metastasis, and hormone escape. This review will focus on the roles and the mechanisms of action and regulation of chemokines in the different steps of PCa development and will discuss the novel strategies that are currently envisioned to target chemokines in PCa.
Collapse
Affiliation(s)
- David Vindrieux
- INSERM, U844, Site Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, Montpellier F-34091, France
| | | | | |
Collapse
|
28
|
Vindrieux D, Réveiller M, Florin A, Blanchard C, Ruffion A, Devonec M, Benahmed M, Grataroli R. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate. J Cell Physiol 2006; 206:709-17. [PMID: 16245307 DOI: 10.1002/jcp.20520] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The apoptotic cell death process in the prostate is known to be under the control of androgens. Tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF-alpha family of cytokines, known to induce apoptosis upon binding to its death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2. Two additional TRAIL receptors, DcR1/TRAIL-R3 and DcR2/TRAIL-R4, lack functional death domains and act as decoy receptors for TRAIL. In this study, we examined whether TRAIL and cellular receptors expression was targeted by androgens during the apoptotic cell death process in the hormone sensitive ventral prostate. The role of androgens was investigated using two sets of experiment. (1) Androgen deprivation associated with an apoptotic process resulted in a decrease in DcR2 mRNA and protein expression in the ventral prostate 3 days after castration. Testosterone administration to castrated adult rats prevented the decrease in DcR2 mRNA and protein levels in the ventral prostate. In contrast, DcR2 expression was modified, neither in the dorsolateral nor in the anterior prostate following castration. No changes were observed in DR4, DR5, DcR1, and TRAIL mRNA and protein levels in prostate after castration. (2) A specific decrease in DcR2 expression was observed in the ventral prostate after treatment of rats with the anti-androgen flutamide. Together, the present results suggest that testosterone specifically controls DcR2 expression in the adult rat ventral prostate. Androgen withdrawal, by reducing DcR2 expression, might leave the cells vulnerable to cell death signals generated by TRAIL via its functional receptors.
Collapse
Affiliation(s)
- David Vindrieux
- Institut National de la Santé et de la Recherche Médicale, Communications Cellulaires en Biologie de la Reproduction, Faculté de Médecine Lyon-Sud, Oullins Cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Grataroli R, Vindrieux D, Selva J, Felsenheld C, Ruffion A, Decaussin M, Benahmed M. Characterization of tumour necrosis factor-alpha-related apoptosis-inducing ligand and its receptors in the adult human testis. Mol Hum Reprod 2004; 10:123-8. [PMID: 14742697 DOI: 10.1093/molehr/gah016] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) is a member of the tumour necrosis factor-alpha (TNF-alpha) family of cytokines which is known to induce apoptosis upon binding to its death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2. Two additional TRAIL receptors, DcR1/TRAIL-R3 and DcR2/TRAIL-R4, lack functional death domains and act as decoy receptors for TRAIL. In this study, the presence of TRAIL and its receptors was investigated by immunohistochemistry in adult human testes. In addition, TRAIL and its receptors were studied in terms of protein and mRNA using western blot analysis and RT-PCR respectively. TRAIL and its receptors were immunodetected according to the different testicular cell types: TRAIL, DR5/TRAIL-R2 and DcR2/TRAIL-R4 were localized in Leydig cells, DR4/TRAIL-R1 was seen in peritubular and Sertoli cells whereas ligand and all receptors were detected in germ cells. Proteins and mRNA corresponding to TRAIL and its receptors were also identified in adult human testes. In conclusion, TRAIL and its receptors DR4/TRAIL-R1, DR5/TRAIL-R2, DcR1/TRAIL-R3 and DcR2/TRAIL-R4 are expressed in the human testis, and are predominantly localized in different germ cell types.
Collapse
Affiliation(s)
- Renée Grataroli
- Institut National de la Santé et de la Recherche Médicale, INSERM U-407, Communications Cellulaires en Biologie de la Reproduction, Faculté de Médecine Lyon-Sud, BP 12, F-69921 Oullins Cedex, France.
| | | | | | | | | | | | | |
Collapse
|
30
|
Vindrieux D, Devonec M, Benahmed M, Grataroli R. Identification of tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) and its receptors in adult rat ventral prostate. Mol Cell Endocrinol 2002; 198:115-21. [PMID: 12573821 DOI: 10.1016/s0303-7207(02)00407-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor-alpha (TNF-alpha) family of cytokines that is known to induce apoptosis upon binding to its death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2. Two additional TRAIL receptors, DcR1/TRAIL-R3 and DcR2/TRAIL-R4, lack functional death domains and act as decoy receptors for TRAIL. In this study, the presence of TRAIL and its receptors was investigated in adult rat hormonosensitive ventral prostate. TRAIL and its receptors were identified in the rat ventral prostate in terms of protein and mRNA. TRAIL and its receptors were immunolocalized in prostatic epithelial cells.
Collapse
Affiliation(s)
- David Vindrieux
- Institut National de la Santé et de la Recherche Médicale, INSERM U-407, Communications Cellulaires en Biologie de la Reproduction, Faculté de Médecine Lyon-Sud, BP 12, 165 chemin du grand Revoyet F-69921 Oullins Cedex, France
| | | | | | | |
Collapse
|
31
|
Grataroli R, Vindrieux D, Gougeon A, Benahmed M. Expression of tumor necrosis factor-alpha-related apoptosis-inducing ligand and its receptors in rat testis during development. Biol Reprod 2002; 66:1707-15. [PMID: 12021051 DOI: 10.1095/biolreprod66.6.1707] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
Tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor-alpha family of cytokines that is known to induce apoptosis upon binding to its death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2. Two additional TRAIL receptors, DcR1/TRAIL-R3 and DcR2/TRAIL-R4, lack functional death domains and act as decoy receptors for TRAIL. In this study, the presence of TRAIL and its receptors was investigated in the rat testis during development. TRAIL and its receptors were immunolocalized to the different testicular cell types. TRAIL and its receptors were also identified in the rat testis in terms of protein and mRNA. Our immunohistochemical studies indicate that TRAIL, DR5/TRAIL-R2, and DcR2-TRAIL-R4 are detected in Leydig cells, whereas ligand and all receptors are localized in germ cells. TRAIL was permanently immunodetected in germ cells from the fetal stage to adulthood, whereas its receptors were immunolocalized exclusively in postmeiotic germ cells. The expression of TRAIL and receptor mRNAs was consistent with the immunodetection of TRAIL and receptor proteins. Indeed, TRAIL ligand mRNA was also identified in the rat testis from the fetal stage to adulthood. The mRNAs of the death receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2, were weakly detected during the perinatal period and increased from the pubertal stage to adulthood. The mRNAs of the decoy receptors, DcR1 and DcR2, were present in the rat testis at all ages studied, but the DcR2/TRAIL-R4 mRNa level was higher from the pubertal period to adulthood. Together, the present findings demonstrate that 1) TRAIL and its receptors are expressed in the testis during normal development, and 2) TRAIL protein is present in the different germ cell types, whereas its receptors were predominantly detected in the postmeiotic germ cells.
Collapse
Affiliation(s)
- Renée Grataroli
- Institut National de la Santé et de la Recherche Médicale, INSERM U-407, Communications Cellulaires en Biologie de la Reproduction, Faculté de Médecine Lyon-Sud, F-69921 Oullins Cedex, France.
| | | | | | | |
Collapse
|